Division of Thermo Fisher Scientific Inc.
Latest From Brahms GmbH
German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company talks to Scrip about how it works, and why it won’t allow the asset to be a victim of strategic decision making.
Jens Pfannkuche is appointed GM of GILUPI, German developer of a circulating tumor cell system.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March-April 2014.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Thermo Fisher Scientific Inc.
- Senior Management
- Christophe Fraudeau, General Mgr.
- Contact Info
Phone: (49) (0)33028830
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.